SPECIAL NOTICE
A -- TECHNOLOGY/BUSINESS OPPORTUNITY Disposable Point-of-Care Testing Device for Nucleic Acid Amplification and Colorimetric Detection
- Notice Date
- 3/24/2011
- Notice Type
- Special Notice
- NAICS
- 238990
— All Other Specialty Trade Contractors
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue, L-795, Livermore, California, 94550
- ZIP Code
- 94550
- Solicitation Number
- FBO236-11
- Archive Date
- 4/26/2011
- Point of Contact
- Connie L Pitcock, Phone: 925-422-1072
- E-Mail Address
-
pitcock1@llnl.gov
(pitcock1@llnl.gov)
- Small Business Set-Aside
- N/A
- Description
- TECHNOLOGY/BUSINESS OPPORTUNITY Disposable Point-of-Care Testing Device For Nucleic Acid Amplification and Colorimetric Detection Opportunity : Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract with the U.S. Department of Energy (DOE), is offering the opportunity to license and develop the Disposable Point-of-Care Testing Device technology for Nucleic Acid Amplification and Colorimetric Detection. Background : Point-of-Care (POC) testing is an emerging market that promises giant leaps for medical diagnostics. Currently, many tests for disease diagnosis are performed at centralized laboratories and utilize expensive instrumentation. The time and expense of transporting samples and purchasing large instruments for testing create a market need for devices and tests that can provide diagnoses in the clinic or even at the home of the patient. While simplified tests for pregnancy, glucose, drugs of abuse, and other protein biomarkers have used techniques such as lateral flow for many years, testing for infectious diseases have required PCR-based assays for analysis of nucleic acids. PCR requires highly purified samples as well as complex instrumentation for detection of fluorescent tags. The current market for infectious disease point-of-care testing is valued at $384 million by Frost and Sullivan and expected to grow quickly. The next advances in point-of-care testing for infectious disease require breakthroughs in assays and devices designed to allow similar detection sensitivity to instrument-based PCR detection, but are low-cost and disposable. Description : Researchers at Lawrence Livermore National Laboratory (LLNL) have developed a point-of-care testing device and assay conditions for infectious diseases. The device is simplified in its design, allowing sample acquisition, preparation, nucleic acid amplification and detection all in one tube. Detection of a Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) reaction is colorimetric, requiring no expensive detection instrumentation and allowing detection by eye. Advantages : · Sample preparation and nucleic acid amplification in a disposable device · Simplified one-tube reaction vessel · No detection instrumentation required · Colorimetric detection capable of being read by eye · Inexpensive reagents and device Application The point-of-care testing device is suitable for nucleic acid-based testing for infectious diseases. Development Status : LLNL is pursuing patent protection for the device and assay developments. The researchers have successfully conducted proof-of-concept validation of the system by amplifying and detecting Foot-and-Mouth Disease virus (FMDv). LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information. Please visit the IPO website at http://ipo.llnl.gov/workwithus/partneringprocess.php for more information on working with LLNL and the industrial partnering and technology transfer process. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL’s Disposable Point-of-Care Testing Device for Nucleic Acid Amplification and Colorimetric Detection should provide a written statement of interest, which includes the following: 1. Company Name and address. 2. The name, address, and telephone number of a point of contact. 3. A description of corporate expertise and facilities relevant to commercializing this technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships Office Attn: Ida C. Shum P.O. Box 808, L-795 Livermore, CA 94551-0808 Attention: FBO 223-10
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DOE/LLNL/LL/FBO236-11/listing.html)
- Record
- SN02408154-W 20110326/110324234200-a38fff45ec681f0eb669c4a3fe2bc1ba (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |